| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MES hemisodium has no biological target. It is a chemical buffer used to maintain a stable pH. The hemisodium salt is used to achieve the desired pH more conveniently than the free acid. It does not interact with biological receptors or enzymes.
|
|---|---|
| ln Vitro |
MES hemisodium is not a drug and has no direct in vitro biological activity. At concentrations used for buffering (10-100 mM), it is not cytotoxic to most cell lines. It is an inert reagent used to maintain pH conditions. The hemisodium form is preferred in many applications because it simplifies buffer preparation. It is a standard buffer component in many biochemical and cell biology protocols.
|
| ln Vivo |
Not applicable. MES hemisodium is not intended for in vivo use as a drug. It is a buffer reagent. It is used in cell culture and in vitro experiments but is not administered to animals. No therapeutic in vivo activity is reported. It is used as an excipient in some pharmaceutical formulations for pH adjustment.
|
| Enzyme Assay |
Not applicable. MES hemisodium is a buffer, not a standard enzyme inhibitor. Its purity (>98%) is assessed by HPLC. Physicochemical properties: MW 217.22, white crystalline powder, soluble in water (≥100 mg/mL), pKa 6.1 (25degC). The buffer capacity is measured by titrating a solution of MES (0.1 M) with HCl or NaOH and monitoring the pH. The effective pH range is 5.5-6.7. No biological assays are applicable.
|
| Cell Assay |
Not applicable. MES hemisodium is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with MES (1-100 mM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >50 mM, indicating low cytotoxicity. The compound is a buffer, not a test agent for pharmacological studies.
|
| Animal Protocol |
No in vivo animal protocol for MES hemisodium exists, as it is not a drug candidate. For acute toxicity testing, female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of MES in water at 500, 1000, 2000, 5000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >2000 mg/kg (low acute toxicity). This protocol is not typically performed for this compound.
|
| ADME/Pharmacokinetics |
Not applicable. MES hemisodium is not a drug and is not intended for systemic absorption. If administered intravenously, it is rapidly excreted unchanged in urine. It is not metabolized. For research use, it is stored at room temperature in a tightly sealed container, protected from moisture.
|
| Toxicity/Toxicokinetics |
MES hemisodium is considered safe and non-toxic at the concentrations used for buffering (10-100 mM). The acute oral LD₅0 in rats is >2000 mg/kg. It is a mild skin and eye irritant. For handling, use PPE (gloves, lab coat, safety goggles), work in a well-ventilated area, avoid inhalation of dust.
|
| References | |
| Additional Infomation |
MES hemisodium (2-(N-Morpholino)ethanesulfonic acid hemisodium salt; CAS# 117961-21-4) is a research-grade Good‘s buffer used in cell culture and biochemistry. It is not an FDA-approved drug. It is used as a pH buffer for biological research, protein purification, and enzyme assays. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C6H13NO4S.1/2NA
|
|---|---|
| Molecular Weight |
205.72
|
| Exact Mass |
412.095
|
| CAS # |
117961-21-4
|
| Related CAS # |
MES-d13;352534-94-2;MES;4432-31-9;MES monohydrate;145224-94-8;MES sodium salt;71119-23-8;MES hydrate;1266615-59-1;MES potassium;39946-25-3
|
| PubChem CID |
53393467
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.108
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1COCCN1CCS(=O)(=O)O.C1COCCN1CCS(=O)(=O)[O-].[Na+]
|
| InChi Key |
KHQSUKMBWPKXOP-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/2C6H13NO4S.Na/c2*8-12(9,10)6-3-7-1-4-11-5-2-7;/h2*1-6H2,(H,8,9,10);/q;;+1/p-1
|
| Chemical Name |
sodium;2-morpholin-4-ylethanesulfonate;2-morpholin-4-ylethanesulfonic acid
|
| Synonyms |
2-Morpholinoethanesulphonic acid hemisodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~486.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8610 mL | 24.3049 mL | 48.6098 mL | |
| 5 mM | 0.9722 mL | 4.8610 mL | 9.7220 mL | |
| 10 mM | 0.4861 mL | 2.4305 mL | 4.8610 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
